Feature / NICE update

04 March 2013

Login to access this content

LoginRegister

NICE published the following guidance in February:

Clinical guidelines

    • CG156 Fertility (update) – The revised guideline recommends couples should become eligible for IVF treatment having tried to conceive for two years rather than the three previously specified. This is estimated to have a non-recurrent cost of about £201,000 for a population of 100,000. If commissioners move to being consistent with access to IVF services across the NHS, in line with the previous NICE guideline, there is also likely to be an increase in the annual recurrent cost of around £129,000 for IVF treatment for a population of 100,000.


    Technology guidance

  • TA274 Ranibizumab for treating diabetic macular oedema

     – The annual cost associated with implementing this technology is estimated as £41,000 for a population of 100,000, based on the standard assumptions in the model once a steady state is reached. It is also anticipated that there will be non-recurrent costs from treating the prevalent population on implementation of the guideline of around £341,000. The manufacturer of ranibizumab has agreed a patient access scheme with the Department of Health, in which a discount on the list price of ranibizumab is offered. The size of the discount is commercial-in- confidence. It is the responsibility of the manufacturer to communicate the level of discount to the relevant NHS organisations

  • TA275 Apixaban for preventing stroke and systemic embolism in people with nonvalvular atrial fibrillation

     – The technology apixaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation is unlikely to result in a significant change in resource use in the NHS. This is because of an estimated comparable cost between apixaban and the other newer oral anticoagulants dabigatran and rivaroxaban

     

    NICE update was prepared by Stephen Brookfield, (senior costing analyst) at NICE

    • Related content